Trial Profile
A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms PROVIDE
- Sponsors Pharmacosmos
- 14 Mar 2017 New data from this trial published in the American Journal of Hematology, as reported in a Pharmacosmos Media Release.
- 14 Mar 2017 Results published in the Pharmacosmos Media Release
- 19 Aug 2016 Primary endpoint (Proportion of subjects with an Hb increase of ≥2 g/dL from baseline) has been met, according to a Pharmacosmos media release.